[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Klawiter et al., 2007 - Google Patents

B cells: no longer the nondominant arm of multiple sclerosis

Klawiter et al., 2007

Document ID
15087906160866816691
Author
Klawiter E
Cross A
Publication year
Publication venue
Current neurology and neuroscience reports

External Links

Snippet

The role B cells and humoral immunity play in multiple sclerosis (MS) is continually evolving. Recent discoveries include advances in lesion classification, identification of B cell clonal expansion in the central nervous system with evidence of antigen targeting, identification of …
Continue reading at link.springer.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Similar Documents

Publication Publication Date Title
Sellner et al. EFNS guidelines on diagnosis and management of neuromyelitis optica
Pittock et al. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin‐4 channelopathies: a decade later
Stüve et al. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases
Disanto et al. The evidence for a role of B cells in multiple sclerosis
Reindl et al. Antibodies as biological markers for pathophysiological processes in MS
Zettl et al. Immune-mediated CNS diseases: a review on nosological classification and clinical features
Jarius et al. Neuromyelitis optica: clinical features, immunopathogenesis and treatment
D'Ambrosio et al. Peripheral blood biomarkers in multiple sclerosis
Salvetti et al. Epstein–Barr virus and multiple sclerosis
Iwanowski et al. Immunological differences between classical phenothypes of multiple sclerosis
Argyriou et al. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system
Bernard‐Valnet et al. Neuromyelitis optica: a positive appraisal of seronegative cases
Redenbaugh et al. Monoclonal antibody therapies beyond complement for NMOSD and MOGAD
Longbrake Myelin Oligodendrocyte Glycoprotein–Associated Disorders
Brandão et al. Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia
Tugizova et al. New therapeutic landscape in neuromyelitis optica
Lutterotti et al. Biological markers for multiple sclerosis
Monaco et al. The link between VLA-4 and JC virus reactivation
Klawiter et al. B cells: no longer the nondominant arm of multiple sclerosis
Bendszus et al. Multiple sclerosis and other demyelinating diseases
Chhibber et al. Evidence‐based review of therapeutic plasma exchange in neurological disorders
US20240317876A1 (en) Treatment Of Multiple Sclerosis And Neuromyelitis Optica
Lysandropoulos et al. Demyelination as a complication of new immunomodulatory treatments
Nouri et al. Neuroinflammatory and demyelinating disorders of childhood
Beyer et al. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings